Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM)
      Google Scholar   
Citation:
J Clin Oncol vol 24 (16_suppl) TPS4205
Meeting Instance:
ASCO 2024
Year:
2024
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
No-Endpoint
Analysis:
Trial-Description-Only
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epreprint
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882  
Corr. Author:
 
Authors:
                     
Networks:
CA136, CA824, COLUMBIA, LAPS-IL057, LAPS-MA036, LAPS-NY016   
Study
Alliance-A022106
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2/3
Keywords: